Dermatol. praxi. 2023;17(4):198-201 | DOI: 10.36290/der.2023.036

Hidradenitis suppurativa in pediatric population

MUDr. Michaela Chmelíková, prof. MUDr. Monika Arenbergerová, Ph.D.
Dermatovenerologická klinika 3. LF UK a FNKV, Praha

Hidradenitis suppurativa is a chronic inflammatory disease, that often starts in pediatric population, unfortunately there is a gap between onset and diagnosing this disease. The early onset of symptom is usually associated with a more serious course of the disease. Early diagnosis let us start appropriate therapy as soon as possible and help us to prevent exacerbations, complications and comorbidities. This article summarizes information about the epidemiology, clinical manifestations, comorbidities and treatment for patients under 19 years of age.

Keywords: hidradenitis suppurativa, pediatric patients, epidemiology, treatment options.

Accepted: November 15, 2023; Published: November 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chmelíková M, Arenbergerová M. Hidradenitis suppurativa in pediatric population. Dermatol. praxi. 2023;17(4):198-201. doi: 10.36290/der.2023.036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slonková V. Možnosti léčby Hidradenitis suppurativa. Dermatol. praxi. 2017;11(4):170-172. Go to original source...
    2. Ballard K, Shuman V. Hidradenitis Suppurativa, StatPearls Publishing; 2022.
    3. Hallock KK, Mizerak MR, Dempsey A, et al. Differences Between Children and Adults With Hidradenitis Suppurativa. JAMA Dermatol. 2021;157(9):1095-1101. Go to original source... Go to PubMed...
    4. Naik HB, Paul M, Cohen SR, et al. Distribution of self-reported hidradenitis suppurativa age at onset. JAMA Dermatol. 2019;155(8):9. Go to original source... Go to PubMed...
    5. Liy-Wong C, Kim M, Kirkorian AY, et al. Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric Patients. JAMA dermatology. 2021;157(4):385-391. Go to original source... Go to PubMed...
    6. Arenbergerová M, Frey T, Gkalpakiotis S, et al. Čes-slov Derm. 2011;86(1):5-11.
    7. Wang B, Yang W, Wen W, et al. Gamma-secretase gene muta­tions in familial acne inversa. Science. 2010;330: 1065. Go to original source... Go to PubMed...
    8. Kimball A, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Annals of internal medicine. 2012;157(12):846-55. Go to original source... Go to PubMed...
    9. Ema.europa.eu. 2021. Available from: https://www.ema.europa.eu/en/documents/product-information/humira-epar-product-information_cs.pdf.
    10. Navrazhina K, Frew JW, Grand D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. The British journal of dermatology. 2022;187(2):223-233. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.